LB Pharmaceuticals awards director 10,000 stock options

LB Pharmaceuticals director Robert R. Ruffolo received a stock option grant covering 10,000 shares of common stock.

Rhea-AI Filing Summary

LB Pharmaceuticals director Robert R. Ruffolo received a stock option grant covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036.

According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, as long as he remains in continuous service through the vesting date. After this grant, Ruffolo holds 10,000 stock options directly.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider RUFFOLO ROBERT R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 10,000 options Exercise price: $27.95 per share Expiration date: June 2, 2036 +2 more

5 metrics

Options granted 10,000 options Stock Option (Right to Buy) grant to director on June 3, 2026

Exercise price $27.95 per share Conversion or exercise price for the stock options

Expiration date June 2, 2036 Option expiration for 10,000 underlying common shares

Underlying shares 10,000 shares Common stock underlying the granted options

Post-grant derivative holdings 10,000 options Total derivative shares following the reported transaction

Key Terms

Stock Option (Right to Buy), underlying security, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

underlying security financial

"underlying_security_title: "Common Stock" and underlying_security_shares: "10000.0000""

exercise price financial

"conversion_or_exercise_price: "27.9500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LB Pharmaceuticals (LBRX) director Robert Ruffolo report on this Form 4?

Robert Ruffolo reported receiving a stock option award for 10,000 shares of LB Pharmaceuticals common stock. The options were granted at a $27.95 exercise price and represent compensation, not an open-market purchase or sale of existing shares.

How many LB Pharmaceuticals (LBRX) options were granted to Robert Ruffolo?

The filing shows a grant of stock options covering 10,000 shares of LB Pharmaceuticals common stock. This entire amount was acquired in a single derivative transaction and is now held directly following the grant.

What is the exercise price of Robert Ruffolo’s LB Pharmaceuticals (LBRX) stock options?

The options have an exercise price of $27.95 per share. This means Ruffolo can buy LB Pharmaceuticals common stock at $27.95 per share upon exercising the options after they vest and before they expire.

When do Robert Ruffolo’s LB Pharmaceuticals (LBRX) options vest?

All 10,000 option shares vest on the earlier of June 3, 2027 or the date of LB Pharmaceuticals’ next annual stockholders’ meeting. Vesting requires Ruffolo’s continuous service with the company through the applicable vesting date.

When do the LB Pharmaceuticals (LBRX) stock options granted to Robert Ruffolo expire?

The options expire on June 2, 2036. Ruffolo must exercise any vested options before this expiration date; after that, any unexercised options will no longer be exercisable under the terms disclosed.

Did Robert Ruffolo buy or sell LB Pharmaceuticals (LBRX) shares on the market?

No open-market buy or sell was reported. The Form 4 shows a grant of stock options as compensation, classified as an acquisition of a derivative security rather than a purchase or sale of existing common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUFFOLO ROBERT R

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NEW YORK 10119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.95	06/03/2026		A		10,000		(1)	06/02/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Marc Panoff, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)